Media headlines about Accuray (NASDAQ:ARAY) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Accuray earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 46.4945598916359 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

A number of brokerages have commented on ARAY. Jefferies Group LLC reissued a “buy” rating and set a $7.00 price objective on shares of Accuray in a report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $5.00 target price on shares of Accuray in a report on Thursday, August 24th. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a report on Thursday, August 24th. Zacks Investment Research raised Accuray from a “strong sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, BidaskClub lowered Accuray from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $5.85.

Accuray (NASDAQ:ARAY) traded up 5.88% during trading on Monday, hitting $4.50. The stock had a trading volume of 436,610 shares. The company’s market capitalization is $374.31 million. The stock’s 50-day moving average price is $4.13 and its 200-day moving average price is $4.45. Accuray has a 1-year low of $3.60 and a 1-year high of $6.39.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Tuesday, August 22nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.05). The firm had revenue of $112.09 million for the quarter, compared to the consensus estimate of $112.00 million. Accuray had a negative net margin of 7.71% and a negative return on equity of 61.62%. Accuray’s revenue was up 18.0% on a year-over-year basis. During the same period last year, the business earned ($0.09) EPS. Analysts expect that Accuray will post ($0.20) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-accuray-aray-share-price/1571741.html.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Insider Buying and Selling by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.